

South Dakota Department of Social Services, Division of Medicaid Services Pharmacy & Therapeutics (P&T) Committee Meeting Minutes

Friday, June 9, 2023

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	X	Matthew Stanley, DO	X
Dana Darger, RPh, Chair	X	Deidre Van Gilder, PharmD	X
Bill Ladwig, RPh	X	Taylor Koerner, DSS Staff	X
Kelley Oehlke, PharmD	X	Mike Jockheck, DSS Staff	X
Lenny Petrik, PharmD	-	Matthew Ballard, DSS Staff	X
Heather Preuss, MD	X	Sarah Aker, DSS Staff	X

Administrative Business

Darger called the meeting to order at 1:02 pm. The minutes of the March meeting were presented. Baack made a motion to approve. Van Gilder seconded the motion. The motion was unanimously approved.

Jockheck introduced a new pharmacist on the DSS staff, Taylor Koerner, 2020 SDSU graduate.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from January 1, 2023, to March 31, 2023. A total of 2,459 PAs were reviewed of which 147 requests (6%) were received via telephone, 156 requests (6.3%) were received via fax, 940 (38.2%) were reviewed electronically, and 49.5% PAs were received via ePA. There was a 25% increase of PAs received compared to the previous quarter which was the result of the ePA implementation effective 1/1/2023. Faxed PAs decreased 88% due to the ePA option provided to prescribers.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from January 1, 2023, to March 31, 2023. The top five therapeutic classes based on paid amount were atypical antipsychotics, skin and mucous membrane agents, disease-modifying anti-rheumatic agents, amphetamines, and cystic fibrosis correctors. These top 15 therapeutic classes comprise 25.82 % of total claims. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid make up 9.3% of total claims. Darger commented on Skyrizi utilization increasing.

Old Business

Eucria review

The committee reviewed Eucria utilization. Darger stated implementing a PA on Eucria would be appropriate and Baack concurred. After reviewing the other states' PA criteria, Baack recommending PA criteria similar to State A with some minor tweaks; adding age criteria of 3 months and shorter trial period of 30 days. Baack made the motion to add PA to Eucria with the minor changes and Ladwig seconded the motion. Darger inquired if there was any public testimony. There were none. The motion was approved unanimously.

Winlevi PA

The committee reviewed the proposed PA criteria for Winlevi. Van Gilder made the motion to accept the proposed criteria and Baack seconded the motion. Darger inquired if there was any public testimony. There were none. The motion was approved unanimously.

Vtama PA

The committee reviewed the proposed PA criteria for Vtama. Van Gilder and Baack recommending removing the dermatology consult requirement. Baack made the motion to proposed PA criteria without the dermatology consult. Van Gilder seconded the motion. Darger inquired if there was any public testimony. There were none. The motion was approved unanimously.

Opioid update

The committee reviewed 1Q2023 opioid outcomes compared to previous quarters from the opioid initiatives. There was a slight increase in opioid utilization and utilizers during 1Q2023 in addition to an increase in total eligibility. Darger commented that the initiatives are continuing to work. Ladwig concurred. Jockheck commented on changing the DUR edits from message to a soft edit for opioid utilization with concomitant utilization with skeletal muscle relaxants, benzodiazepines, anticonvulsants, medication assisted therapy, or prenatal. Baack was concerned regarding the prenatal edit. Stanley supported the soft edit for skeletal muscle and benzodiazepines but express his concerns of abrupt benzodiazepine cessation. Jockheck will provide more information and what other states are doing.

New Business

Antidepressant PA review

The committee reviewed the antidepressant PA reviews. After reviewing the sertraline PA requests for quantity limits, Ladwig made the motion to remove quantity limits on sertraline. Stanley seconded the motion. Darger inquired if there was any public testimony. There were none. The motion was approved unanimously.

Asthma guidelines

Dr. James Wallace, MD, pediatric pulmonology specialist, provided a presentation on the new asthma guidelines especially the updates focused on children.

Aker announced her resignation as the Medicaid Director. She expressed her thanks to the committee. The committee wished her well.

Adjournment

The next meeting is scheduled on September 8, 2023. The December and March meetings are tentatively scheduled for December 8, 2023, and March 1, 2024, respectively. The motion to adjourn the meeting was unanimous, and the meeting adjourned at 2:58 pm CT.